Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€17.14
Change (%) Stock is Down 0.02 (0.12%)
Volume12,868
Data as of 02/20/18 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
13-Feb-2018ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France--(BUSINESS WIRE)--Feb. 13, 2018-- Regulatory News: ERYTECH Pharma (Euronext: ERYP- Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the selection of Triple Negative Breast Cancer as the ne... 
 Printer Friendly Version
12-Feb-2018Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com ... 
 Printer Friendly Version
08-Feb-2018ERYTECH to Present at the 2018 BIO CEO & Investor Conference
ERYTECH to Present at the 2018 BIO CEO & Investor Conference LYON, France - February 8, 2018 - ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference, being held February 12-13, 2018 at the New York Marriott Marquis in New York City.... 
 Printer Friendly Version
08-Jan-2018Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –December 31, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 8, 2018-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top